Stock Price
15.71
Daily Change
0.19 1.22%
Monthly
-7.37%
Yearly
-0.44%
Q1 Forecast
15.60

Adma Biologics reported $134.22M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Adma Biologics USD 134.22M 12.24M Sep/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 84.51M 330.97M Sep/2024
Takeda JPY 1.19T 80B Dec/2025